Loading Events

EORTC Brain Tumour Group Virtual Meeting

Virtual Event

The EORTC Brain Tumour Group Virtual Meeting will be held from 14:00 to 17:00 CET.

14.00 Welcome & Activity Report M. Weller
   
14.05 Report from EORTC HQ M. Vanlancker
   
14.20 Update from BTG Committees  
5 Translational research & pathology P. French
5 Quality assurance E. Razis
5 Quality of life L. Dirven
5 Imaging M. Smits
5 Meningioma M. Preusser
5 CNS metastasis E. Le Rhun
     
15.00 Update on completed clinical trials and research projects  
15 26053-22054: Phase III trial on concurrent and adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON intergroup trial. M. van den Bent & P. French
5 1320: Trabectedin for recurrent grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group M. Preusser
     
15.30 Ongoing clinical studies  
     
5 1308: An international randomized phase III study of observation vs. immediate adjuvant radiotherapy for WHO grade II newly diagnosed and recurrent meningioma patients after total surgical resection (ROAM). M. Preusser
5 1419: BTFC Longterm survival in glioblastoma. C. Hertler
5 1608: Study of TG02 in elderly newly diagnosed or adult relapsed patients with anaplastic astrocytoma or glioblastoma: a phase Ib study, STEAM. E. Le Rhun
5 1635: IDH mutated 1p/19q intact lower grade glioma following resection: wait or treat? The I-WOT study. M. van den Bent
10 1709: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma. P. Roth
     
16.00 Planned clinical trials  
10 1634: Standard therapy vs. personalized intensity-modulated therapy for newly diagnosed medulloblastoma in adults: an international phase 0, phase Ib and randomized phase II study (PersoMed-I). P. Hau
10 1926: Romiplostim plus lomustine or lomustine alone at first progression of MGMT promoter-methylated glioblastoma: a randomized phase II open label multicenter study. E. Le Rhun
5 2031: AMG 510 in KRASG12C positive non small cell lung cancer patients with brain metastases. M. Preusser
5 2013: Treatment and outcome of patients with primary brain tumors diagnosed according to the revised WHO classification and cIMPACT recommendations. M. Weller
5 2046: Isoquercetin for the prevention of venous thromboembolic events in glioblastoma: a randomized placebo-controlled phase III trial. E. Le Rhun
     
16.40 Current issues, new initiatives & any other business M. Weller
     
17.00 End  
     
  Next General Meeting: March, 2021